Prostate Cancer Patient

Treatment with the IDO inhibitor INCB024360 increased lysis of human tumor cell targets by peptide-specific CTL
Caroline Jochems, Anna Kwilas, Young-Seung Kim, Martin W Brechbiel, Massimo Fantini, Simon Metenou, Romaine I Fernando, Peter S Kim, Sofia Gameiro, James Hodge, Robert Newton, Jeffrey Schlom, Kwong Y Tsang

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P275; DOI: 10.1186/2051-1426-3-S2-P275
DRB1*11 allele expression and HER2 pre-existing immunity may predict benefit in breast cancer patients vaccinated with the HER2 modified AE37 peptide vaccine
Eleftheria A Anastasopoulou, Panagiotis Tzonis, Sotirios P Fortis, Louisa Mahaira, Christoforos Vaxevanis, Alexandros Ardavanis, Elizabeth A Mittendorf, George E Peoples, Constantin N Baxevanis, Michael Papamichail, Sonia A Perez

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P427; DOI: 10.1186/2051-1426-3-S2-P427
Generation of human T cells directed against an agonist epitope of Brachyury, a transcription factor involved in human tumor cell epithelial to mesenchymal transition (EMT)
Benjamin Boyerinas, Jo A Tucker, Diane J Poole, Caroline Jochéms, Claudia Palena, Jeffrey Schlom, Kwong Y Tsang

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P202; DOI: 10.1186/2051-1426-1-S1-P202
S82. Proffered paper: In-vivo testing of PSMA-targeted T-cell immunotherapy for prostate cancer
Z Liu, SB Papa, J Morris, J Maher

Journal for ImmunoTherapy of Cancer Mar 2014, 2 (Suppl 2) I20; DOI: 10.1186/2051-1426-2-S2-I20

Log in using your username and password

Main menu

Log in using your username and password

You are here

Prostate Cancer Patient